Photo from wikipedia
In a phase I trial of chimeric antigen receptor T cells targeting CD19 and CD22 in younger patients with relapsed or refractory B-cell acute lymphoblastic leukemia, toxicity was manageable, and… Click to show full abstract
In a phase I trial of chimeric antigen receptor T cells targeting CD19 and CD22 in younger patients with relapsed or refractory B-cell acute lymphoblastic leukemia, toxicity was manageable, and five of 12 patients had complete responses.
Keywords:
cd19 cd22;
younger patients;
aids younger;
cd22 aids;
targeting cd19
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!